All posts by matthiaswacker

Simulate SubQ

Our latest work on drug release testing of microparticles was just accepted by the International Journal of Pharmaceutics. A great work by the young first author Ge Fiona Gao. One year ago she won a Best Abstract Award of the AAPS Annual Meeting, now she has finalized her work. The release assay elucidated the influence of proteins on microparticle release and how they affect discrimination between different batches of drug products. Even without affecting solubility, proteins stabilize particles and may affect the performance in the subcutaneous tissue. A mechanistic model helped us to understand the influences of such parameters and formulation characteristics on pharmacokinetics.

The PBNB model: Unlock your PK data

Today, our manuscript on the Physiologically-based Nanocarrier Biopharmaceutics (PBNB) Model was finally accepted for publication by the European Journal of Pharmaceutics and Biopharmaceutics. I explained the purpose of this model in my talk during the Explain-My-Research Virtual Conference in May 2020 and will go more into detail during a Live Webinar organized by Malvern Panalytical in July. Rather than providing a ‘convenient fit’ only, the model is designed to link the pharmacokinetics of nanocarriers to a physiologically-based distribution. Interesting parameters you may obtain with this model are, for example, the targeting capability and the mean residence time of the nanocarrier in the blood plasma. A lowered plasma concentration often indicates that more drug has been released from the carrier and is not available for targeting any more. The PBNB model recognizes such changes and calculates how much carrier-bounded drug is accumulated before this release happens. Expressed as a fraction of the total dose, this is the targeting capability (Ftarget) . The mean residence time of the carrier (MRTc) in the blood plasma indicates how much time the delivery system had for this accumulation process and is a marker for targeting accuracy.

Some of the simulations our PBNB model is capable of are provided on the servers of our collaborator isee systems.

Guest judge @ SPDS

I was very happy to act as a guest judge for the Society for Pharmaceutical Dissolution Science. For the last 10 years, my group has been passionate about developing novel release assays and it was good to have a conference putting this important part of drug product development in the spotlight. Students from all over India submitted their work on drug release testing. Congratulations to the finalists.

Save the Environment

It is really difficult to publish translational manuscripts these days, but this is a prime example of a good collaboration between pharmaceutical and environmental sciences. As pharmaceutical scientists, we sometimes have to use a certain material to facilitate drug therapy. But if we have a choice and more than one coating or one polymer actually works, why not choose the one which is best for the environment? This study helps you sort that out.

Predicting Nanomedicines

A wide variety of models have been established to predict the performance of nanomedicines for the peroral route of administration, but only a handful for injectables. Liposomal temoporfin has been evaluated in a phase I clinical trial. This investigation was focused on the prediction of the performance of liposomes in humans using preclinical in vitro and in vivo data. Congratulations to our young researcher Laura Jablonka who is responsible for this great accomplishment. Also, it is a prime example for international collaborations by involving researchers from Germany and Singapore…

Best Abstract Award @ AAPS

We were informed that Ge Fiona Gao received the Best Abstract Award for the AAPS Annual Meeting 2019 with her abstract “Elucidating Human Pharmacokinetics of a Subcutaneous Microparticle Depot Formulation: Impact of Drug Formulation, Patient Population and Clinical Setting“. We are proud to have her in our team and wish her a successful visit at the conference in San Antonio, Texas!

Our paper @ Adv Drug Del Rev

Our new article on the challenges associated with market translation of nanotechnology-related products has been accepted by Advanced Drug Delivery Reviews.

The international team of experts has done a great job in providing their expertise. Thanks to you Margareth Marques (USP), Choo Qiuyi (HSA), Mukul Ashtikar (Fraunhofer IME), Thais Correa Rocha (ANVISA) and Susanne Bremer-Hoffmann (EC-JRC).